<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00701337</url>
  </required_header>
  <id_info>
    <org_study_id>0507402</org_study_id>
    <nct_id>NCT00701337</nct_id>
  </id_info>
  <brief_title>Effect of 17ß-estradiol on Inflammatory-immune Responses in Post-menopausal Women According to Administration Route</brief_title>
  <official_title>Effect of 17ß-estradiol on Inflammatory-immune Responses in Post-menopausal Women According to Administration Route: Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this pilot study conducted in post-menopausal women is to evaluate the effect of&#xD;
      17ß-estradiol administration on inflammatory-immune cells, namely antigen-presenting cells&#xD;
      (monocytes/dendritic cells), and more precisely on their activation by inflammatory stimuli.&#xD;
      This study will allow us to determine our ability to recruit menopausal women and to&#xD;
      characterize the optimal primary end-point among the numerous criteria tested&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although the beneficial effects of hormonal replacement therapy (HRT) against osteoporosis&#xD;
      and climacteric symptoms have been clearly established, randomized studies recently revealed&#xD;
      that the combined administration of oral estrogens and medroxyprogesterone acetate increases&#xD;
      the incidence of coronary events and strokes during the first months of treatment.&#xD;
      Furthermore, oral estrogens significantly enhance IL-6 and CRP secretion. This increase in&#xD;
      the plasma concentration of inflammatory markers probably results from a direct effect of&#xD;
      oral administration on the liver, since i twas not observed with estrogens administered by&#xD;
      transdermal route.&#xD;
&#xD;
      Our experimental data in ovariectomized mice demonstrated that the chronic subcutaneous&#xD;
      administration of17ß-estradiol (E2) enhances the expression of pro-inflammatory cytokines by&#xD;
      Th1 lymphocytes, Natural Killer T cells and monocytes/macrophages. This pro-inflammatory&#xD;
      effect of E2 could play a role in the deleterious vascular effects observed in randomized&#xD;
      studies, especially by favoring plaque instability.&#xD;
&#xD;
      Our aim is to determine whether E2 administration in menopausal women leads to an&#xD;
      inflammatory phenotype of circulating antigen-presenting cells, especially monocytes. Indeed,&#xD;
      evaluating the inflammatory status at the cellular level probably gives more precise&#xD;
      informations than plasma cytokine concentrations to predict the ability of estrogens to&#xD;
      enhance inflammatory processes. We first propose a pilot study in order to determine&#xD;
      enrollment feasibility, as well as the optimal biological endpoints to assess monocyte&#xD;
      activation status. These latter criteria will be then used in a future randomized study&#xD;
      comparing two routes of E2 administration (oral vs transdermal).&#xD;
&#xD;
      The present study will include 34 menopausal women. After the inclusion visit, three visits&#xD;
      will be performed with the collection of a 50 ml blood sample and the isolation of&#xD;
      circulating immune cells (monocytes).&#xD;
&#xD;
      The following criteria will be studied before (V1 and V2) and after 30 ± 3 days of E2&#xD;
      treatment (V3:&#xD;
&#xD;
        1. expression of surface activation molecules.&#xD;
&#xD;
        2. Secretion of cytokines in response to several Toll-like receptor stimuli.&#xD;
&#xD;
        3. IL-6 and CRP-US plasma concentrations.&#xD;
&#xD;
      We will first assess the intra-individual variability (V1 and V2). At visit 2 (V2), the&#xD;
      subjects will be randomized to receive E2 either by oral (n= 17) or transdermal (n= 17)&#xD;
      route.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the feasibility of a future multicentric randomized trial : estimation of the number of subjects required</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>variability and repeatability of the biological parameters studied</measure>
    <time_frame>1 month</time_frame>
    <description>number of circulating immune cells, expression of surface molecules by monocytes, secretion of cytokines following TLR activation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility of the recruitment, enrollment and follow-up of menopausal women</measure>
    <time_frame>End of study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Postmenopausal</condition>
  <arm_group>
    <arm_group_label>1 Oral</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oestradiol by oral administration - Estrofem 2 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oestradiol par patch - Estrapatch 60microg/24h</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oestradiol</intervention_name>
    <description>oestradiol 2 mg oral route 30 days</description>
    <arm_group_label>1 Oral</arm_group_label>
    <other_name>Estrofem</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oestradiol</intervention_name>
    <description>oestradio transdermal patch 60ug by 24 hours 30 days</description>
    <arm_group_label>2 patch</arm_group_label>
    <other_name>Oestrapatch</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women with confirmed menopause (duration : 1 to 5 years)&#xD;
&#xD;
          -  No contra-indication of hormonal replacement therapy due to medical history&#xD;
&#xD;
          -  Mammogram without significant abnormality (&lt; 12 months)&#xD;
&#xD;
          -  Normal body mass index (BMI) (19 ≤ IMC ≤ 25 kg/m2)&#xD;
&#xD;
          -  No treatment with estrogens and/or progestatives and/or SERM (specific moduator of&#xD;
             estrogen receptor) and/or phytoestrogènes ongoing or stopped for less than 3 months&#xD;
&#xD;
          -  No clinical or biological abnormality or treatment indicating the presence of an&#xD;
             infectious or inflammatory disease.&#xD;
&#xD;
          -  No participation to another clinical study during the 3 months before the inclusion&#xD;
&#xD;
          -  Ability to sign the consent form.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre GOURDY</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital University Toulouse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Seillet C, Laffont S, Trémollières F, Rouquié N, Ribot C, Arnal JF, Douin-Echinard V, Gourdy P, Guéry JC. The TLR-mediated response of plasmacytoid dendritic cells is positively regulated by estradiol in vivo through cell-intrinsic estrogen receptor α signaling. Blood. 2012 Jan 12;119(2):454-64. doi: 10.1182/blood-2011-08-371831. Epub 2011 Nov 16.</citation>
    <PMID>22096248</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>February 22, 2007</study_first_submitted>
  <study_first_submitted_qc>June 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2008</study_first_posted>
  <last_update_submitted>May 10, 2017</last_update_submitted>
  <last_update_submitted_qc>May 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Estrogen Replacement Therapy</keyword>
  <keyword>menopausal women</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

